These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25087677)

  • 1. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.
    Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G
    Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
    Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
    Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
    McGovern I; Chastek B; Bancroft T; Webb N; Imran M; Pelton SI; Haag MDM
    Int J Infect Dis; 2024 Sep; 146():107160. PubMed ID: 38969330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.
    Mannino S; Villa M; Apolone G; Weiss NS; Groth N; Aquino I; Boldori L; Caramaschi F; Gattinoni A; Malchiodi G; Rothman KJ
    Am J Epidemiol; 2012 Sep; 176(6):527-33. PubMed ID: 22940713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
    Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D
    Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly.
    Lapi F; Marconi E; Simonetti M; Baldo V; Rossi A; Sessa A; Cricelli C
    Expert Rev Vaccines; 2019 Jun; 18(6):663-670. PubMed ID: 31155968
    [No Abstract]   [Full Text] [Related]  

  • 13. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
    Puig-Barberà J; Díez-Domingo J; Varea AB; Chavarri GS; Rodrigo JA; Hoyos SP; Vidal DG
    Vaccine; 2007 Oct; 25(42):7313-21. PubMed ID: 17889411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age.
    Zedda L; Forleo-Neto E; Vertruyen A; Raes M; Marchant A; Jansen W; Clouting H; Arora A; Beatty ME; Galli G; Del Giudice G; Castellino F
    Pediatr Infect Dis J; 2015 Jan; 34(1):73-8. PubMed ID: 25037034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.
    Loperto I; Simonetti A; Nardone A; Triassi M
    Hum Vaccin Immunother; 2019; 15(5):1035-1047. PubMed ID: 30735465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
    Pott H; Andrew MK; Shaffelburg Z; Nichols MK; Ye L; ElSherif M; Hatchette TF; LeBlanc J; Ambrose A; Boivin G; Bowie W; Johnstone J; Katz K; Lagacé-Wiens P; Loeb M; McCarthy A; McGeer A; Poirier A; Powis J; Richardson D; Semret M; Smith S; Smyth D; Stiver G; Trottier S; Valiquette L; Webster D; McNeil SA; ;
    Vaccine; 2023 Oct; 41(42):6359-6365. PubMed ID: 37696717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes.
    McConeghy KW; Davidson HE; Canaday DH; Han L; Saade E; Mor V; Gravenstein S
    Clin Infect Dis; 2021 Dec; 73(11):e4237-e4243. PubMed ID: 32882710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
    Iannazzo S
    J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons.
    Lapi F; Domnich A; Marconi E; Rossi A; Cricelli C
    Expert Rev Vaccines; 2022 Nov; 21(11):1647-1653. PubMed ID: 35984048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.